Compare PJT & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PJT | ICUI |
|---|---|---|
| Founded | 2014 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.6B |
| IPO Year | 2015 | 1995 |
| Metric | PJT | ICUI |
|---|---|---|
| Price | $165.14 | $158.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $178.50 | $169.00 |
| AVG Volume (30 Days) | ★ 494.7K | 278.8K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.66% | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | N/A | ★ 1.20 |
| Revenue | $1,713,671,000.00 | ★ $2,231,262,000.00 |
| Revenue This Year | $11.12 | N/A |
| Revenue Next Year | $9.98 | $4.46 |
| P/E Ratio | ★ $23.03 | $135.15 |
| Revenue Growth | ★ 14.77 | N/A |
| 52 Week Low | $127.73 | $107.02 |
| 52 Week High | $195.62 | $162.82 |
| Indicator | PJT | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 56.13 | 60.68 |
| Support Level | $164.04 | $140.69 |
| Resistance Level | $175.70 | $160.78 |
| Average True Range (ATR) | 7.67 | 5.30 |
| MACD | 0.87 | 0.21 |
| Stochastic Oscillator | 71.00 | 76.73 |
PJT Partners Inc is an advisory-focused investment bank that offers a portfolio of advisory services designed to help its clients achieve their strategic objectives. The company delivers a range of strategic advisory, capital markets advisory, restructuring and special situations, and shareholder advisory services to corporations, financial sponsors, institutional investors, and governments around the world. It also provides private fund advisory and fundraising services for alternative investment strategies, including private equity, real estate, hedge funds, and private credit. The company generates its revenue from advisory fees, placement services, and others. Geographically, it generates maximum revenue from the United States, followed by the United Kingdom and other markets.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.